Creating a new treatment for skin fibrosis in scleroderma patients
Official title: Development of a Novel Therapeutic Agent for Skin Fibrosis
Funded at Fibrobiologics, LLC · NIH-11006900 · Data updated 2026-11-12
This study is testing a new treatment called M10 to help improve skin problems caused by scleroderma, a condition that makes the skin stiff and thick, and it's designed to be safe and effective for patients dealing with this issue.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibrobiologics, LLC NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,518 |
| NIH project number | 1R41AR084935-01 |
| Project ID | NIH-11006900 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with scleroderma who experience significant skin fibrosis.
✕Less likely to help
Patients with scleroderma who do not have skin fibrosis or those with other unrelated conditions may not benefit from this research.
What this research studies
This research focuses on developing a novel peptide therapeutic agent, M10, aimed at treating skin fibrosis associated with scleroderma, an autoimmune disease. The study will investigate the antifibrotic activity of M10 using primary skin fibroblasts from affected patients. By leveraging advances in peptide formulation and synthesis, the research aims to create a drug that is highly specific and has low toxicity, potentially improving the quality of life for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for skin fibrosis in scleroderma patients, improving their skin condition and overall health.
How similar studies have gone: While there have been advancements in treatments for scleroderma, the specific approach of using the peptide M10 is novel and has not been extensively tested in this context.
Where this research is happening
-
Fibrobiologics, LLC
Charleston, United States Active
Researchers
- Principal investigator: Bogatkevich, Galina S — Fibrobiologics, LLC
- Study coordinator: Bogatkevich, Galina S
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.